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1. U'e  .. nufccturers a.re  tree to f'i:: tho price of proprietary medicinal pro<.luots. 
Host  of them apply the compuls ''r'J prioes, nnmely the -;rholesol.e  price 
~hich th' pharnu:l.cist  himself must  pay  •  In other cases, manufacturers ro-
ooDmlond  a  sales price whioh  io usually applied. 
2.  Ph~~oists, on the other ho.nd 1  do  not  enjoy such freedom.  'l'hey  must 
oonforu to the provisiono of tho ."German  pha.I'1'll<.i.Oeutioal  Tariff'~'· (Deutsche ' 
ArznoitC'..:o).  This. tariff is oontainod in a.·  deoroo  issued by the  I1iniot~J 
of Pill:moo1 as laid dol'm  by !..rtiole 37  of tho  lo.w  on  cl.rugs  C'rzneinlittol-
geootz,  10 :Yay  1961  - DC!.ll.  1  !1Dt>OOO  533).  It is empol-Iered to fix prioea 
end prioo r:mrgins  for tho sa.lo of dru.crs  and to  ena.ot  provisions  dotormi..'linc 
prioos in pharmacies.  In doinc this the  !Iin~stry must  take account  of the 
intcrcot ·or consumers  and of ~~oists  aa  public institutions and 
SUP!>liors of drugs. 
The  provioions regarding price formation  concer.n·medeoL~es prepared by 
the p:1armaoist. 
The  pharmnoist•s margin tor proprietary drugs varies according to the 
wolcsalo price. The  preael'lt  ~~rgin was  fixed by the decree of 6 June 
1968  (3..:\nz.  no. 107). To  tho uholesnl.e prioe applied on a  normal mo.rl:et 
·D!Wit  be  addod  1 
a  70  ~~ inoree..so  up to 2.,}0  J)I!  (CTOSS  profit 42.6  ~) 
a.  68  ~;  incroa.sa  from 2.63  to 7.60  DII  {eros  a  profit 40.5  ~) 
a.  63  ;~  incre~e from  8.  21  to 14.  28  DM  (G'I'OOS  profit 38.7  ~) 
-
53  r"  •  ·a  ,.,  J.~1orcaso f'rom  17 to 24.75  DM  (gross profit 34.6 5&) 
a.  47  ~~ increase from  26.80 to-38 DM  ({:.TOSS  profit 32  %) 
a.  t,2  ~~ increase from  42. 53  to 57  DI·t  (gross profit 29.6  %) 
a.  35  ~~ increase over 68.40  DU  (gross  p~fi  t  25.9  %) 
'. 
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3.  Hotrover,  c.  dr~f't  law currently bof'ore the Bwia.estag provides  for a 
reduction of 3.4 ~in the  disponr,j.~. pharmacist  18  mc..~.r~  tl...'t).d  for 
a  m~~·jmum wholesaler's margin.  · 
On  the  o.the~ .hand,  tho  discounts granted by the dispensing pha.rma.oiats 
· to,  th~ aicl-:ness  insurance  :f\mds. will decrease from  7 to 5 )a. 
4. Finally,  in order to etlS'qro  bottGr market  transpe!.renoy,  an i.'ldependont 
oommit.t.ee  must  be set up.  It lfill publish informetion notes on all the· 
important medicines  (oonq:>Osition,  eftioaoy,  aide-of'f'eots,  price') whioh 
will bo distributed to tho  siol~asa-insuranoe tund.S  and to the,  doctors 
affil'ie.tod thereto• 
\ 
5.  BASFi  Bayer;  Boehringer !Io.tt1heim  and Hoechst  have  given notico of their 
intention of avoiding price increases in 1976  for  lcrgo-turno~er medicines~ 
without,  however,  oommittincr themselve·s to ":f'reezL'la" the prices. 
The  Pho.rmc.oeutioal  Industry .l\ssocia.tion {Bundeaverband der Pba.rmazeutisohen 
In~trie) 4~, in addition~ recommended its members  to reduce expenditurO 
on  eamp~ea, aoientitio tnto~tion and  advertiatnB. 
.. 
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Tho  lc  .. tr  of 9 July 1975  (lionitour bclce of 30 July 1975)  empowers  the :linistor 
for r::oonomio  1lffa.irs to fix m~d.num prices for proprietary drugs  and other 
medicines  1  ma.::imum  wholesale and retail margins  and oeilings on the  diSCO\'l.:.'ltG 
grnnted by dispensing pha.rrnaoista.  11b.e  Ifi.nister must  consult the Price Com-
mission. 
l• Tho  ?rice Commission 
The  royal decree of' 8  August  1975  l~rs down  the membership  and the duties 
of this Commission  (Honiteur bolgo of 19  .\ugust 1975).  It .is  compos~d of 
equal nwabcrs ot representatives of the  consumers  and of representatives 
of the producers, the import  ora  and the distributors. It also includes 
represente  .. tivos of the ministrioo ooncorned.  Its general task is to  gi~·o 
its o:;>i11ion  on all qu.Gstions  rolatil1S to the pricco of proprietary d.russ, 
. to koop  tro.o~.: of the situation  rc~~.rding the prices· of proprietary drugs 
and to ocl:o  suggest  ions  oonoentinG tho prico policy to be  adopted,  and to 
give opinions on the criterio. to be  t~ten into consideration \ibere. special 
decisions on  prices are  conoe~1od. 
In a.ddi  t ion, it expresses opinions  w~1enevor maximum  soles prices aro fixed, 
t-fhenever tho levels of the marcintJ  are :fixed and \·rhcnover the discounts 
grantod by tho ·diaponaing  phc~coiata aro rogulated. 
II. Criteria for fixinG prices 
These oriterio. were  laid doun by tho royal decree ot ~1 December 1975  {Uonitour 
bolge of 16 nooombcr 1975). 
(a) l!hon  tlcl:ing hio decision;  tho II:inistor must  ta..'co  into account  ono  or moro 
ot tho following general. criteria: 
1. t'rond of sales on  the· Dolaian market  and of tho oorrespondin& turnover; 
.;. J 
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2. trond ot expendituro by t~e aiol:neas  inauro.nbo  f\mds; 
3.  impo..ct  ot pri·cea  on oonsumQrs; 
4•  COStS  Of the factors Of prodnction,  Of importatiOll 01' of distribution; 
s.  lovol ot advertising, ot medical  uitorma.tion expenses and  at.\lea 
o::ponaosJ 
6.  level ot wholesale  and rot  ail margins  J 
7•  incidence ot V.A.T.  rG:.t081 
8. research and investment; 
9. ottoot on tho protito.bility end tho  pl~oing on  Qn  indue~rial ~ia 
ot all tho Wlderta.kinn-o  in the aootor; 
10. hoalth interests ot the public. 
(b) Tho· Ili11istor must  also  t~c il1to  consideration ono  or more  of the  tollot-~ 
epeo!fio ori  toria1  which must  tirst have boon  ex:.mined by the Price 
Commission: 
. . 
1.- components· of the ox-'ttor!:s -or importer's prioo (starting materials 
end l)nol:aging,  aala.rios,  t·mges  and  social. s~curity contributions 
in rospoot of production and  mar~eting, royoltios,  expensaa for 
anr.J.:,'"Bis  and inspection,  for research and development, _general  oxpenaos, 
advertising, medioai  in~o~tion, other aalea .o:pcnaea,  profit); 
'  ' 
2.  otfcot_  ~t wholesale  and  rot~il margtn1; 
3.  tnoidonoe ot V.A.T.; 
4•  bc.lc.noo  sheets; 
5.  tho number ot units oonto.inod in oa.oh  package  ·~d  'tho strcnith ·  por 
unit; 
6.  inveatmont  and, numbers  employed; 
7. ma.rkot  and  competition oondi  t ions and ef'f'oot  on  export; 
a.  oompnrison with the current. priooa tor identical or comparable 
produats in other countrioa tzith a  similar atancUI;rd ot liVinlJJ 
./. -5- XI/117/76-E 
9·  comparison wi  tll the ourront  prices in Belgium  for medicines that nrc 
intcrcomparable  from  tha therapeutio.standpoint; 
10.  health interest,  inoludtng the therapeutic value' of the medicine, 
socio-economic, technical and scientific interest for society. 
III. Application of the law 
(a) The  law on  the system for pricing propriot·a.ry drugs  seems  to be  of an 
experimental nature•  It is to be  applied only ~il  31  December  1977• 
Thereafter,  tailing,any new·~ling, the general law on  prices will apply 
(law ot 30  July 1971). 
(b) The  ministerial order of 10  February 1976  (Moniteur bolge of 12  Febl'\lD.ry 
1976)  laid down  the application procedures. 
1. The  prices shall not  o:ccoad  tb~ao that were  current on  ll August  1975 
or have  been fixed ~inco then. 
2.,Requcsts for  fixin~ or r~ising prices must  include  info~~~ion enabling 
an opinion to be  giv~n on  the criteria aet out  in Section II·above. 
~·1hcre no  repiy is  recciv~d from  the administration within 8:  period 
of two  months  follow~ng the request  tor fixing the .P~ce, this shall 
be deemed to signify approval. 
3.  The  wholoaaler'a margin shall not  exooed 13.1 %  ot hie aelling 
price, not ot V.A.T.  (or BF  73  per packago). 
Tho  Pharmacists margin  shall not  exceed 31  ~ of his selling price, 
not of V~A.T.  (~r :SF  250  per package). 
.;. ! ! 
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Pursuant to Article 30  of the law on  pharmacies  (Law  No  248. ot- 2  July 1962), 
the ·selling price of medioi~es to  ce~um~ra is ,.fixed  i~ a.. tariff iaid down' · 
~Y royal·  deere~.· This taritt Oo~prisel th~  .pric~' of p~prt~t~y  ~druse  and~ 
I  '  •  '  '  ..  •  '  '  '  .;.  '  '  •  '  ·~  'If  '  '  •  '  •  ~  • 
other modioinea  which c&nn.Oi  be 'sold 'at  ..  a~ lower or;  higher •  price  (fixed I'  ~ 
pric~s), ·  .  ~··~;.t·;  ·1  ~  ~:·:  •..  ~  "  .•  ,,..  '  •  "  ·- '  ·•  ··"·  ':. ••  ... :  ' 
Tho  system for fixing the prices. of ·medicines must  be  ex8mined against the· 
'  '  I  to 
background of the strict control exercised by the Danish authorities, 
'  ) 
particularly with .regard to tho eeographioal distribution of dispe~sariea 
•  .  ,  ,  .  .  I 
~  (334 pharmacies  in  1~74). It is by means· ot the .tariff that the _average net 
'  '  -': 
income  of tho  diaponsirig pharmacists is fixed.· The  decisive factor that  :- ~ · 
intluencos 8ny ·chango· in tho selling price ot medicines is  ~be estimate 
ot tho posaibili  ty of th~ net  income of the~e pharmacists  rea.ching t~ 
level fixed. in. advano~ by  ~ho Minister for the.  ~tor~or (this level ia 
at  present  equivalent to· tho mnual  ..  salary ot the  .. ~e~·  ~ioi~  ~  a" 
pu~lic hospif&l.)~· ::.:;  i· · 1  .'-!·  -~  -~  '·f  ...  .·:~  :  }  '~i·  _·:~  ·:  I  ·t:  :.::'  :·1.  ~ ·  .  .'d  · .:  ·~:. 
1. The  tarift 
~ 
A  I 
The  provisions of the tariff that  Qonoem  the fixing ot the price ot 
propricta.ey ~gs  (a.elling:.prt~oe  to.th~· pubLic}  ·a.re- ~-follow':.· · .·.~·  · 
.~ ,  :  ,  '  '  '  ' ,!  1  :  •  ,  '  •  :  of·,  ;,  _..  \  "  .~  ,  ':  •  ~  ,.  ~  •  1 
(a) In the caae ot prop:riet  nry druge  tor whi  ah ·tho pho.rmaoiat '• pl.U'-
ohaaing price 18  Ikr 20  or loss' this prico is inoroaeod by 40 .  % 
'  .·  :'  '  '  \:  .·  . 
+ lkr o.  70. or by 70  ~ ot the  pharsna;o~st '.a  purchil.eing price,  which-
~  J  l  •'  I  ;  "  •. •  , 
ever ia the lesa. 
In the  case ·of proprietary tor which the pharmacist 'a purch~~' 
prico exceeds ~  20' 'this p~ice is  inoroase~ by 1kr s.7o  + 30 % 
·ot tho amount  in exooss ot lkr 20.  ·  ·  ' 
1 
•  · 
In tho  caae ot certain products  (e.g. insulin), the pha.rma.ciat 'a 
I  J•,  •  t 
purchasing price  Ot\ll  only be  increased by 10 ~ 
(b)  An  addition ot 2) %  is med.e  to the amounta  thus obtained. 
'  t  •  I  •·  '  ' 
./. -
I 
/• 
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(o) The  selling price to the. consumer ia obtained by adding certain 
supplementary costa that may  arise in respect of ethical medicines 
or ot certain· spe.cia.i  .. sonices ·(supply  ~t·  .ni~t, -£~;~~~~e)~ 
The  amount  of these supplementary oosts is fixed bJ"  the tariff''  which 
also contains  prov~sions relating to the discounts granted to. hospi-
tcls, to public' establishments, etc. 
2.  ~ac dispensing pharmacist's purchasing price  (Apotoksindk~spris- A.I.?.) 
Tho  dia~cnsinc pharmacist's purchasing' price (i.o. the producer's or 
im:~~~or's selling prioc) is registered but is not  subject to approvql 
by tho public health 'authorities. Howover,  Artiolo  23  of Law  No  327  of 
' 
26  June  1975  on modicinoa  provides that tho Danish :Ionopoliea  Commission 
{ik>nopoltilsynet) shall suporviso the prioes calculated by manufacturers~ 
importers or wholesalers ot p}Mrma.oeuticol  products  ·in accordance· wi~h 
its torms  o~ reteronce·.  / 
.;. '  I 
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I. System  applicable to propriete£Y druB!·  which are not  advertised  publiol~ 
~ 
The  system ia.  governed by the decree ot 5 April 1968  (No  25.202:  ».o.s.P. 
9 April 1968)  and amendments  thereto. 
· Manutaoturera tix the maximum  production aaiea  price,  tree ot' tax, 
'oy  adding together the following oo,mponentaa 
\. 
A.··  Industrial prime  costs 
This  is obtained from ·the avorage  purchase prioo during the 
two  months  prior to the month  of manufacture,  together with 
I 
control costs duly motivated,  actual losses in manufacturing, 
and  approach coste ·duly motivated.  The  maxiUXWD  peroentap ot 
euch losaea is fixed by the decree. 
·(b) Cost  of direct labour  ••••.-••••••a•••••••• 
Thi•  covers  waeoa  or •Alarie• paid to atatt dirootly omployod 
in the manufacture  and packaging ot product  a,  and, aooial costa 
relating thereto. 
Theae  oover: ·- wages  or salaries and social coste paid to 
stnff not  working on  the  production side {cadres, 
supervision,  checking,  maintenance  and handling 
excluding management,  commercial  an<l  adminietr&-
tive departments) 
.;. ..  .  . 
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•- materials  consumed {coal,  fuel,  cleani\ng 
products,  wat·e·r,  gas,  electricity) 
- rent  and  insurance of industrial premisos 
amortization of materials and industrial 
premises 
B.  Financial,  administrative and commercial  copts  .. 
(a) Commercial  costs  ··-··-·=••:a•==· 
' 
These  are costa incurred tor the sale of. products, the aalos 
force labour,  packaging,  mailing and advertiainB• 
(b) Administrative costs ·  ········•=:a••····-·· 
These  rela.to to staff not  coming under the ·p~.ceding' cate-
gories,  rants, rental charges  and·  insurance ot administrative 
buildings, etc. 
~ 
These  are the costa of capital used (interest, premiums,  etc.) 
C.  Other  costs 
They are 1imited to 5 %  ot the ·"I)J,$.  p;riQ~ .. ot products. 
(b) Resoarch costs ·  ·········-·=·· 
The  real a.m.otmt  of this expenditure will be allowed for 
provided it is receded in a  apeoial  ~count. 
.;. lilt  .-.·· •• 
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(o) Remuneration ot own  tunda 
·······-~···········-~--­ , . 
..  .  ' 
· ·  This  ia  .· caloulatGd by applJ1.ng 5 '%  interest, net ot company 
.  :  .  . ...  ·  '  . 
t~,. on  0wr1  tun<14  given in the. moat  recent public balance-
aheet. 
D.  Production sale price 
This is obtained by adding together these different  factors ,to. 
which the manufacturer adds  a  proti  t  margin which he himself 
fixes.  In this way·produota·  ~ae  industrial prime ooata  aro 
).ow  are not  penol.ized  •. 
A.  l~'holesa.le price 
•  t 
.. 
Thia.ia the purchase prioe'paid by·the ~l~aaler, i.e. tho 
production eale price plus  VAT. 
B.  Pharmacist's price 
This ia the pnrcha.se  price paid by the pharmacist.  It ia obt~ed  . 
by applying to the preceding price a  maxi~ gro•• brand ~te 
fixed at 10.70 ~ (Ordor No  25.795 ot .24  July 1970  -.B.o~s.P. 
26  July 1970). 
:C •.  Price to the· public 
This is obtained by applying a  maximum  gross  br~d rate tixod 
at 33.44 ~ (Order ot 24  July 1970) to the pha.rmaciat '• price. 
'  '  •  f 
D.  Schedules  ot price  vari~~ta 
Manufacturers  and wholesalers are free to fix scales ot prico 
variants to take account  of the size of orders.  Theae  aohedulea 
must  be lodged. 'd  th. the competent  authoritiea and they alone 
are applioablo. 
./  . 
•  l '  ... 
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The  maximum  sales prices to the public proposed by the  ~uf'aoturors 
- must  be notified tot 
- The  Directorate-General for Prices and Internal Trade 
- ~e  :.11nistry ot Scientific  an~ Industrial  Developm~t 
- The' Ministey ot Pu.blic Health 
at least thirty dqa betore the date on 'Which  it is proposed to 
imploment  them. 
The  Directorate-General tor Prices and  Internal Trade may  object 
to  ~hem  • 
•  ~y  subsequent_  price alteration ia subject to the same  obligations. 
_, 
However,  the time-limit ot thirty days is reduced to eight da1a 
where  prices are lowered. 
-II. System tor proprieta.rx druse  reimbursed by Social Securi  tz 
_  tJhen  -a.  manufacturer applies to  ha.~~ his product  included on tb.e list 
of drugs  reimbursable by Social Security, his application must  be -
accompanied by a  prioo elip in acoordanoe with the  provision~ mentioned 
herototor. 
If euoh product  is accepted for inclusion on the list, thon it is 
·  t~s price which _must  be  charged by the manufacturer.  If the price 
proposed by the manufacturer is not  accepted,  the Ministry fixes the 
price on the basis of proposals  from  a  commission of representativoe 
of the sickness insurance t'unds  and pharmaceutical  industry associations. 
By  Order No  76-14/P  (B.o.s.P.  of 7 Februar,y 1976),  the maximum  selling 
prices of 230  medioinGa  that are refundable to socially insured 
porsons  wero  roduced .by 1  - 5 'fo.  This  reduction applioa mainly to 
expansive medicines  (antibiotics, tranquilizors, eto.). 
·'  .. 
./. 
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On  t-ho  other hand,·  firms  which in 197 4 sold products whose  pro  ducor 
price was  not  greate~ t~, FF  4 can increase prices by 13.3 'to  60  f-. 
.  .  ·~  .  .  . 
. ~  . 
III. System  for medicinal  products  advertised publicly 
. Those  products mu.st  comply with ·the price  pro~emming aoheme,  iD 
accordance with an Ordor dated 14  March  1972. 
'' 
(i)  '  .  '  . 
Undertakings  employing 20 persona or more: 
Freedom  to  fix production prl.oes if agreements  have  boen  concluded 
with the Direotornte-Genaral for Prices  and  Internal Trade  cithor 
by the professional organizations or by the undertaking~ them-
selves.  These  aGreements  lay down  a  programme  for price developments 
for a  given  period by reference to an  average nati9nal indicator. 
:But  price increc.sea may  not  exceed the limits tixed by the agree-
ments. 
,.  '1  i. 
(ii) Undertakings  employing lese than 20  peraona~  ... 
Freedom to fix pricos.  •' 
IV.  Szstem for imported proprietary drugs 
Bo  meaaurea  appear to bavo  been taken in thia reiaz'd,._". , · 
*  ..  * 
A report,  which  ie at  ill: con~ident·ial, on  the possibility ot modi tying· tho 
present  system ot price fixing,  was  recently torwa.rded to the Minister tor 
- I  . 
Public Heal  tb by the "Guinard" working party. 
, '.' . . 
.....  '  .  ' . 
·~ ..  '  ,  ..  .;  .  . : 
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• 
ITALY 
Pursuant to Artic'te 125 ot the .Act  consolidating tho Health Laws·,  approved 
by Royel  Deoree lio  1265 of 27  July 1934 ancl  subsequently amended,  branded 
pharmaceuticals must  be sold to the public at the prico shown  on. the label, 
I. Institutiona.l,framework. 
A. · The  Ministry fo;r  Health 
The  price of new  medioinos is tixod by the I&iatr.r to~ Health whon 
it authorizes the marketing of the product. 
B.  The  Inter-ministerial Price Committee  (I.P.C,) 
Tho  rovis'ion ot the prioo of proprietary drugs already on the markot 
falls within the  oompotonoo  of the  I.P.C,  Sot up by  Decree-Law Uo  347 
ot 19  October 1944,  this committee is presided over by the President 
of tho Council of Ministers  and is composed of ten ministers(namely 
those for Finance,  Troa.sury,  Agriculture  and· Forestry,  Transport, 
'  ' 
Industry and Commercet  Public Works,  Labour  and Social Security, 
Fore).gn.  Trade,  Bud.got •.  state-subsidized industries l and  three experts. 
~e Committee  ia  ~sistod by an advisory body,  the  Central frioe 
Cornmiasion,  which  conducts enquiries ond makoa  proposals to it. 
The  Commission  consists ot representatives ot t·he ·Ministries,  employers, 
workers,  consumers  and  ~presentative• of the regional Governments ot 
'  .. 
Sicily and Sardinia. 
This structure also exists e.t  provincial level:  in each province there 
is  .. a  Provincial Prico  Commission  and a  Provincial Advisory  Commission. 
c. ,Tho  Inter-ministerial Economic  Planning Committee  (I.E.P,C.) 
Sot  up by  La.w  No  48  of 27  I•'cb~"l.ry 1967 1  this ·committee is presided 
over by tho President of tho  Council of Ministers  and·  includes  mnny 
minieters.  Subject to  exo~iae ot the powars conte*ed on the  Council  .  .  '  ...  ' 
'  .. 
''  .;. 
,,  ,. i. 
\ 
i' 
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····u. 
·t<~~'t·\. 
ot lfulisters it establishes, in particular,  th~  g\.lideline~ tor national 
·'  ' 
economic policy.  . .  . 
On  27  July 1971 it issued a  first diroctivo fixing the prices ot 
medioinea  (distributed by the press aervioe ot the Miniatey for tho 
Budaot  and Planning)  and  on  2 Jfa.y 1975  &  eeoond direotive (Guetta 
Ufticiale No  143  of 3 Juno 1975). 
•"'  ..  ·• 
'  . 
II. _Tho  new  method ot p~ice fixf9s 
. . 
The  aims  of the  Intorministerial Committee  are aeen .trom the 
ruoi~ala ot the  firs·~  clire·ctive to be as  follows& 
( 1)  To  improve  knowledge  of "elementary'' production costa  J 
(ii) To  revise prices in the light of these coats, at the same 
time  improving production in thia aeotorJ · 
(iii) To  reduce  ma~koting costa; 
(iv)  To  reduce the number ot branded ~eutioale  and 
pa.cka.gings} 
(v) To  encourage scientific research; 
(vi) To  extend this method,  at_  a  second atage1  to veterinary 
products. 
(b) Criteria laid down,by  tho directives 
This is arrivod-at by add1ng together the coat ot the starting 
. materials,  tho packaging and the value  added.  '''Pbe  value  addo~ 
·  ··'·- -·· .....  is  d~temin.ed p~imt\rily by  reference to the labour cost  plus 
.  an amount  calcu.lo.tod by applying parameters  r.esult~~. f'~m 
·  ~.·.:  \he  .. studY  ~f th~  "'fun.~  ion of the  fir~;-s  .. coat  which the I.].P.c. 
•  I',  baa undertaken  t~ establiah.  This  tunct  ion will bo determined 
. ; on the basis ot o.  somple 8urvey with the exoluaion ot corte.i.D 
~  . 
_taoton  ~lnt~.  to non-applicable foaturee ot :tbe  firm  (aize  t 
teohnologioal.  lovel~ qualit7 ot products)." 
./. 
.., l<  j!JI•  •  -~·:  ,..  . 
[ 
'. 
----.  --.  ~  ....... --·-··  -~  .. -·:  .-··;-·"' 
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The  aim  ia to reduce existing advertising costa to onG  third. 
Advertising of popular branded pha.rmo.ceuticals will' conttiluo 
to be supervized by the Ministry of Health. 
Hence,  the present  costa incurred in sending tree samples, 
brochures,  journals and any other advertising.material will 
only be recosnized to the extent of four-fifths. 
These  tigures will be reduced in tho  course ot subsequent 
price revisions  .• 
(3)  .!8-~ras_s~i£111i!ig,  .te!.oArg,h_an,d_d,iV£1£Pm.ent.L. 
An .increase ot 4 %  of the ttm:lover will be  intended for research 
and development.  However,  an additional percentage  (which must 
I  t'  •  I 
not  ~xceed 10 %  of the turnover· on  each propriet8.17 drug)  can 
be  accorded to firms that are able to show 'that their research 
expendit~ exceeds the-4% mentioned above. 
Royalties  ar~ considered as  price components  under the. same 
conditions as  resoe.rch  e:x:pendit~. However,  they shall not 
exceed 7 ~ of tho· turnover on  each  p:rOpr~eta.ry clrug. 
'l'he  d.ireotivos also apply to imported, products.  For the coat 
evaluation of starling material that is original in ita 
composition and hns  not  yet been used on  the national mnrl:et, 
standard analysis criteria for industrial coats will be used. 
I 
Firms  will bo  required. to submit  an outline ot the product ion 
process  80 as to enable this industrial cost to' be  ev8J.uat~. 
./. 
'  ' ·· .. 
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~o) Other provisions of the diroctive 
(a)  A general price catnloguo ot proprietary drugs  (Prontuario 
generale dei prozzi) was  to be  published during the first half 
·  ot 1973,  but tho publication date was  subsequently postponed 
to 20 November  1975  and has not been adhered to. 
It.will include  (i) the prices revised, 
(ii) e.n  assessment  of certain items · 
(technical snd sciontifio information, 
somples)  tor tho purpose  a  ot detormining 
the prices ot new  medicinal products, 
(iii) procedures for subsequent  price alterations. 
•  .. (b)  However,  regulation (provedimento)  No  13/1975  (G.U.  ot 3 June 
1975)  allowed an  inoree.so ot 12  fo  in the price• of proprietary 
dru.gs. 
(c) Manufacturers'  discounts to aooial secnu'ity organisation• will 
be abolished with. effect trom the entry into force ot tho now 
prices  • 
. (d) The  authorization to place 'drugs  on the market  will be suspended 
'  or w1 thdrawn if tha nooesaa.ry factors  for the revision ot 
priooe aro not  euppliod.  'f)raf't  la.wa  will bo  introduced to  inoroaao 
the -registration tax on branded pharmn.couticals  and to  onsuro 
that the number ot authorizations to place such products on tho 
market  corresponds ·to their actual ueo. 
III. Current practice 
Tho  practice toll9wed hith~rto will be  oontinuod until the new  method 
ia applied. 
·./ . 
.  ' . .  ,. 
•. 
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A.  lfntiono.l  Products 
·The Uinistry tor Health f'ixos the price when  the product is placed on. 
the market. 
The  selling price to tho public is calculated on the basis of the 
I 
industrial cost of the procluct,  to .which.  a:-e  added the· overheads  and· 
distribution costs and tho wholesalers'  and pharmacists'  margins by 
·application of predetermined coefficients and ot parameters that va:ry 
in invorse proportion to tho industrial cost. 
B.  Imported products 
T1hon  applying for reffi,stra.tion,  an importer must  turnish proo:r ot tho 
prioo applied in the country of origin by means  of a  document  dra.wn up 
by tho authorities in that country and stamped by the Italian conaul..c..r 
author!  ties. 
Throe  cases  ID1J3  occur: 
1. Original branded pharmaceutical 
If the branded pharmaceutical is original in its oo~poaition, i.o. 
it it is totally dissimilar to ~  other national branded product, 
tho enloe  prioo ia oalculntod on tho baeis ot the price to tho 
public in the country of' origin, plua  customs  and  tr~port costs. 
2.  t3.imilc.r  branded phnrnmccutical  identical to a  national branded product 
Thoso  aro  foreign  br~..ndod pharmaoouticals which  ha~o the same  com-
position as a  national branded product.  For these, the price is 
f'i:md at the same  lovol· as that of the national product  • 
. 3. Similar branded phamaocutioal not· identical to  a.  national branded 
l)roduot 
Foreign and na.tiono.l.  brnndod phnrmaoeutionls  do  not  have the ·sa.mo 
.composition but 'thero ia an attinity in thoir composition and thoir 
thorapoutio e:ttocta.  /  • • 
! 
.I 
I 
I 
! 
J . '. 
'I  l 
. \ 
,  I 
t  ,, 
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''  lo  •  ~  I,  •  • 
. Products are  examined  ind.i~dually in order to determine whether . 
it is possible to apply the price of the national product or  it~ an 
increase should be allowed instead to take into account the valuo 
ot tho additional aubato.ncos  (which are not  such as sUbstantially 
to alter the characteristics of tho branded product bein&  compared) •. 
c.  Pfice of drugs .reimbursed· by sickness insurance  tup.d.s' 
.  .  . 
Sinco  Law  No  692  ot 4. August  1965,  it has been compulsory to give a 
disco\Ult  to social· seouri  ty organizations on tho  p~blic price ot drugs 
oonaumod  by persona ooverod  by soo'ial aocuri  ty. 
D9oroo-La.w  No  7  45  ot 27  October 1970  f'ixed the discount  on the aelling 
prico to the pbulio at. 25  %,.  18 %  to be borne by the manufacturers, 
. 1  ~ by the  w~leaalers and  6  tfo  by the  pharmacists~  · 
·Thia  discount will be aboliohod when  the now  method ot ·price tixinc 
ia applied.  \ 
,· 
•  I  f  •  I  .. 
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LUXEMBOURG 
The  main  provisions regarding the price of branded pharmaceuticals are con-
tained in the Regulation of the Grand  :J)J.ohy ot 28  July 1962. 
I. System  for national branded pharmaceuticals 
Those  are products manufactured and packaged in tho Grand  !Alchy which do 
.not  ha.vo  any original equivalent in a  foreign country. 
T.be  maximum  production sales price to the wholesaler ia eatablishod by 
adding together the  tollo~ng items: 
·  (a) Production costs whiCh  consist  of: 
(i) The  cost  price of raw materials· 
(ii) Cost  price of packaging materials 
(iii) 1~ages and salaries and social costs relating to statf working 
on production 
(iv) Cost  price of electricity,  gas,  fuel  and  water 
(v) General  industrial costs,  industrial amortization,  amortization~ 
of research and control  instruments,  maintenance  and.  repair' 
costa,  rentnl on .industrial buildings,  insurance, t.axos 
(vi)  w.-~.goa  and anlo.rio•  and aocinl  cha:rso•  rolnting io atB.tt .. 
engaged in re·sea.rch,  control and soionti:t'io information,. 
plus the costs of running the laboratories. 
(b) Other costs and'benofits 
These  may  not  exooed  a  flat-rate amount  equal to the following 
percentages of the total amount  of production costs listed und.or 
point  (a.)  above 
120 %  if the cost  prico of tho  raw materials USQd is leas than 3  F 
90  %  it the price is botween 3  and 10 F 
60 %  it the price is 10 F or more. 
~I·  . ''  I 
{ 
l., 
I. 
l 
f, 
i  '. 
l 
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l1here  the Ministry of Economic  Affairs ·so authorizes,  those pel'-
contages may  be  incrensed to 140 %,  110' %  and' 8o %  respectively 
for a  period of five years  commencing  from. tho date when  tho 
branded pharmaocut ica.l is put up for sa.lo if this has new  thor&-
.  '  '' 
. peutio properties and ia the result ot resear~ carried. ou~  ~ 
entirely in the Grand  ~ohy'~  .. 
·  The  wholes~ler'a margin,  which must  be approved by iho !ti.nistry -ot 
Eoonorni o  Affaire, · ia at present fixed . at .12.; ~ ot the p)larmaciat 'a 
purchase price.  . . 
·.i  ;. 
01  i  . 
•  i 
This ia the pharmacist '8  purchase price increased by 50  fo. · 
II. System  for branded pha.rma.ooutioals originating in or coming  trom BelS.wn 
The  Regula.  tiona ot the Orand Duchy  ot 29  March  1977 ~(Memorial A No  21 
ot 9 April 1971)  and ot 10 July 1973  (Memorial  A 43\ ot 28 Jul7 1973) . 
are applicable in thia.' rega.rd. 
Profit margins  on produote originating in or coming  from Belgium are 
fixod  M  tollowas 
15.21% ot the wholeaaler1a.pruchase price (13.20  ~ ot his sales prico} 
46.70  ~ ot the pharmacist's purchase price (31.83% ot his a8les price)  ' 
'  '  .... , ...................  ,  .. ..., .. -.......  ' 
Howevor,  public prices  (including 2 %  VAT),  may  not bo  more  than 97 •5  'f, 
ot. the public prices  (including VAT)  o~rative in Belgium. 
.;. 
. . .-----------.-------~----···-~··;·"··~ 
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III. System. tor other branded pharmaceuticals 
1'lhoro  no  ou.stoms  duties  a.ro  charged on branded products  im~rted 1 _the 
snlos price in  Luxembo~g may.not, be .moro than  10 %  in excess of the 
sales price in the  country of origin. 
t~cro duty is charged, this price may  not be over 19  ~in excess of 
the sales price in the country of origin in the case of drl.lgs  imported 
in bulk or over 14 %  in excosa  tor produ:ots  imported :t\lll.y packed. 
j  ~  .. 
I',.· 
•, 
.  .  '  .. ;. 
~""""""'  .......  ~--------·-------------------·---·-'-··---~····--····  -· .... ' 
~· ... \ 
I 
..  . 
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~ . ' 
nETHERLANDS  ------
....  .  . : 
At  present no  legal provisions exist regarding .the  pri.oes ot branded p~ 
ceuticals. Manufacturers a.ra  therefore·  responaibl~ for fixing prices. 
~owever, ·agreements under private law. govern the relationship between the 
various categories in this sector. Thus,  an agreement  on trade in d:ru.gs  . 
(Handolsconventie)  between manu:fnoturera,. importers  and wholesale  '\i~ributora 
tixe.• tha maximum  price ma.rt;ins,  save in ro~a.il ·trade. 
Similarly,  a  retain trade 88l'Oemont  (~con)  goveme relatione ·between 
pharmacists.  · 
./. - 23- . XI/ll7h6-E 
UITIT.CD  KING:OOM 
1.  General 
In British. t_erminology medicines  fall into two  classes,  ethi.cal  and . 
non-ethical.  Ethical medicines  are not  a.dvertisod to the  public,  and 
p~~sicians do  not  ~ually prescribe  non~thical-medicines. Some  ·ethical 
medicines  can only/be made  nv~lable by pharmacists on prescription, 
but  others  ma.y  be sold ovor the counter without  prescription. Non-ethical 
medicines  are advertised for sole direct to the public. 
Physicians  are free to  prpscr~~e ~ha' medicines they think best  tor the 
benofit · ot their patients•  an~ Ph:a:rmacists  a.re.  bo~d to dispense in 
accordance with the proscription pres~nted to them.  Pharmacists buy 
pharmaceuticals through wholesalers usually, but  sometimes direct  from 
nk~ufacturers. Pharmacists nrc  reimbursed by the Health Departments 
in tho case of National Health Service  (NHS)  proscriptions ,(about 
97  por oont of the. total nwnbor)  1  and by the patient ln the case ot 
privato ,prescriptions.· 
2. Control of manufacturers'  prices 
Prices t':.re  controllec;l under the  arrangements of tho- VolWlta.ry Price 
Regulation' Schemo  (VPRS),  whose  terms  are negotiated between the 
Hor..lth  Dopnrtmontn  Mel  tho  /ladoo1n.t1C)n  nt tho Dritiah Ph!\rfni\Ocutioll 
'· 
Industry.  Tho  achomo  o.pplios to all  companies  supplying modioinea  , 
proscribed Wlder the mrs.  Tha  major companies  a.ro  asked "to  provido 
annu.o.l  financial  returns giving tho breakdown of sales,  costs and 
.  - . 
capital attributablo to. their business in NHS  .medicines,  supported. 
by Md reconciled with tho  published accounts  tor thei_r. whole buainess 
(sma.lle_r  companies aro pn:rtly or' ~olly  ~xempt  ~ro~  ~his requirem~t  ) • 
.  /. ' 
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Tho  Dopc.rtmcmt ·then aasessca  the profitability o.t  eaoh compMY'a  s3loe · 
to tho lms  in relation to the  oa.pi tal allocated to tha.t  part ot tho 
business, taking account  of -raseC'.roh,  investment  and  any other special 
f'oo.tures  ot the company.  If the  Depa-rtment  considers that profitability 
is too high,  negotiations aro opened with the  company  with a  view tq 
securing· price reductions.  Tho  Department 'a practice  ~a to request  an 
over~l prioo reduction which the oompaey"  is ~o  to ·distribute among  .  . 
·  its produot"a  a.a  it thinks tit, and not to ask tor reduotiona on  indi-
vidual products. 
Companies  are tree to  inoroa.se  prices of their minor products as they 
think necessary without  reference to the Department,  but they are askod 
t~ justifY increa:ses of major products.  Companies  mey  argu.e  that the 
profitability as shown  by ,their annual ·tinancial_rotlu-na is too  low. 
It the ·Dopa.rtment  &grees  t  an overall  in~reaae will be settled, which 
again tho  company  is troo to distribute among  i_ta  products  aa with 
price roduotiona. 
) 
~cse arrangements  for  ro~l~ting prices _oover  tho total sales ot 
medicines to the NHS,  tho.t  ia both specialty and generic medicines, 
whether prescribed by general practitioners or in hospitSla.  They  are-
essentially appropriate .to the ·bulk ot the 'buainoas that ia the proscribing 
of specialities by  gener~ praotition~~, and thore are variations ~ 
t,ho  a.rrangoments  tor genoriq. .F.eaorip~io~  ·and hospit.&l  purchaairig~ 
'  I  :  .'  l  I  \,  '\  t.·;,: •!  •f' t#  • 
. ·' 
'  ~i 
3. Oono'rio  proeortptiona 
The  price reimbursed to, tho pharmacist  for genorio medicines  (that  1~ 
prescribed by their non-propricta.r,y name)  and  preparations dispensed 
on National.Hoalth  Servt~o proscription• ia bnsic~ly the not price for 
the ti.ppropriate qtiant i ty oha.rB"Oablo  by the manufacturer or wholesaler  •. 
•  As,  however,  the majo.rity of go~erio medicines  end preparations aro · 
produced by a  number ot di:ff'oront  manufacturers it is not  poaai  ble . to 
eata.bliah common  prices :PS3a.blo  by all pha.rmaoiata  and because ot thia 
averago :reimbureemen-t  pricoa tor tbeee medioinea  are oaloulatecl by 
./. ·' 
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moans  of a  weighting formula.  This  formula takes into account  the  .. 
shares in the toto.l market  or four  firms  who  together proVide  70  to 
~  8o  ~: of tho tra.de  in standard medicines  and of SU.PPlias  to  pharmacists~ 
Prices are subject to monthly revision and  are the subject of consul-
tation with the Central ln!S  (Chemist  Contractors)  Committee,  the/rctcil 
pharmacistS I  national roprosentatives, before  introduction. 
The  prioo  reimbursed for any medicine  which although generically prescribed, 
is  o~1ly available in proprietary form  is that of the lowest  priced 
propriotary medicine which ia generally ava.iln.blo to  al~ pharma.Qista. 
' 
4.  HOspital  purchases 
Many medicinal products used in National Health Service hospitals aro 
bouaht  direct  ~Y hospital authorities under contracts placed by 
Regional Hospital Boards. 
Itoms  tor which a·regional contract  cannot  be  justified either on  grounds 
ot qUnntity or price a.d.vnnto.a-o  are bought  W'lder  local arrangements·. 
Central contracts placod by the Department  o~ Henlth and Social Security 
arc only arranged where  thero are substantial prioo advantages or to 
ensure qualit7 control.  These  contracts are  ver,y  limited in number. 
Although the no got iations under the  VPRS  rerate only to the  cost ot 
· modicin.a.l  prorlucta  proooribod by  gonora.l  pro.oti  t ionora otrood prioo 
olk~gos  cnventu~lly rofloot  in prices charged to hospital authorities. 
It is also  common  tor mk~ufaoturers to offer hospital supplies at  , 
.  . 
prioos considerably lower than those charged to tho ·chemist. tor supplies 
.  '  . 
under the General  Pra.Qtitioner Sorvicea. 
.,;. 
I •( 
~·  . 
·~ 
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Accounts are met  by  individ~~ hospital authorities from  fUnds  alloontod 
by the Exchequer. 
5•  StD.tutocy  powers 
Sootion 5 (i) of tho.Emorcenoy Laws  (ro-Enactmonts and Repeals) Act.l964 
empowers  the Secretary of stnto by order to provide for controlling 
maximum  prices to be  charged tor any medical supplies required for the 
purpose 9! tho National Hoolth Service Acts.  llo  such order has so tar 
been ma.do.  Prices ot JnQdicinoa  provided outaide the Nat_i~ Health 
Service are not  subject to statutory controls. 
6. Reimbursement  ot pharmacists under the NHS 
The  cost of materials usod by a  pharmacist  tn dispensing NBS  prescri9tions 
is cnlculated in aocord.Mco  with tho provisions of  ,tho  Drug Tariff' (usina · 
the wcrd "drug" in tho  eenso of medicines).  Tho  Tariff is·  prepared on 
behnlf ot the Seorotar,y of Stnto for Social Sorvi9os in accordance With 
·  Regulation 26  ot the lnts  (Gonoro.l  ~dical t\lld  Ph.1.rmo.ceutioal· Services) 
Re:~lo.tiona 1966.  In addition to detailing tho calculation ot peyments. 
for medicines,  appliances nnd reagents, it specifies the grade or quality 
of medicines to bo  supplied.  Payment  ia also made  for the cost ot 
containors; thia allownnco is paid on  every proscription dispensed and 
is an  ~verage ot tho actual coat of containers usod1  as ascertained 
by rogular oontainor ooat  Qn~irioa. A'profoaaionnl toe ia aleo  pnid. 
As' in tho case ot  generic· products, tho prioos for  ~1 other med.icinos 
and a.pplionces  are  reviewed  ~nthly to. take account  of any  pri~o chonsos 
by manufacturers and such  ~hMgos ~  ·aimi.la.rly tho  aubj.e~ of consult:lt.ion 
with tho Central Nils  (Chemist  C~htraoto~)  ·c~aimittoor ,before  il'ltrod~ction  • 
.  /. 
• • 
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1•  ptioos ·of private presoript_ions 
Thoro  is no  mandatory method.  of pricing private prescriptions but 
pharmacists normally use  t~~t recommended by the Pharmaceutical Society 
of Groat Britain. Under this method the.  ph~Irul.oist  charges the cost 
.price of tho prepnration  C'.nP,  any contninor,  plus  25  1o  as  osta.blishrnont 
clL.1.rc;c  and a  foe of 30  p  or,  whoro  it is greater, tho retn.il prica of 
propriet~ preparations dispensed in their origin~ packs.  An  e~ra 
I 
fc~ of 12-1/2 p is oho.rgod for dispensing medicinos  oontrollod by tho 
Dc.ncrorous  Drugs  Act  1965  and ot 50  p  for an urgent· proscription 
dispensed outside normal  hours. 
8. Prices of over tho  counter salos 
Pre~~ations available tor counter sale without  a  presori)tion are 
noruk~ly sold  ~t retail !)rico  •  or·  wholesale price plus  50 1-
~··-~·····~,  ...  ~-fi#I/WIIIIIil"---.,..,......~·-·  ..... ""'·'·"· .) 
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Ireland 
1.  General 
Jttedicines  in ·Ireland are oiassed as ethical, which mS\f  be promoted to the 
medical profession but .not  otherwise advertised,  and non-ethical which  are 
promoted-direct to the consumer through media advertising.  Ethical medicines 
include those which ~  onlY be dispensed on  a  doctor's prescription and  some 
which are sold by pharmacists over the counter without prescription.  Non-
.... 
ethicals do not .require a  prescription~ 
2.  Source 
Pharmacists obtain their supplies from  manufacturers or from  wholesalers. 
All new  medicines must  be authorised,  on  the advice ot the .  National Drugs 
Advisory  Boa.rd1  bu.t  .there is no restriction on  the number ot med.ioinea 
" 
marketed in the country. 
3.  Price Control 
There is limited' price control.  Some,medicines are imported in,a manufactured 
state and since their prices are fixed outside the . jurisdiction thq are not 
subject to control.  The  basic ingredients of others are imported tor final 
processing and in this situation while the price ot the raw materials ia not 
subject  ~o control,  increases in prices attributable to  the proceaatns under-
taken in this country must  be notified to the Prices Commission. 
4.  Price of drugs to the patient 
Under the General  U~dical Service scheme  some  37.5 "of the population are 
entitled to obtain medicines free of charge.  These are dispensed b,y. the retail 
pharmacists  virtual~ all of whom  participate ·in the scheme.  For medicines 
dispensed in this WQY  the pharmacist  is  current~ re-imbursed by  the State, 
the ingredient cost of the item (or trade price) plus 38p fee plus 6p towards 
con~ainer and other costs. 
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Tbe  remainins 62.5% ot the population must  obtain their medicines  trom 
pharmacies at retail prices.  These  are not laid 4own  by statute but  in 
practice are normally calculated· as trade price  ~t the preparation plus 
'  . 
....... -
5o%,  tor over the counter sales. Where  the preparation is prescribed by a 
doctor an additional dispensing fee of_50p is added.  In the·majority of cases 
part of th&  cost of prescribed medicines  can be  recovered by the patient from 
health boards where  the cost  in respect of a  month  exceeds  ~ 5.00. 
5.  Price of medicines to Hospitals 
Medio~nea purchased by hospitals or health boards attract discounts agreed 
with the association representi.ng the ma.nufaet~ers. The  discount prices 
vary according to the quantities ordered,  varyiDB from  trade. price leas  15~ 
to- trade price leaa 5~ Individual hoapi  tala can sometimes. negotia-te more 
ta~ble  term~ 
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